Effective bladder preservation strategy with low-dose radiation therapy and concurrent intraarterial chemotherapy for muscle-invasive bladder cancer.

PURPOSE: The aim of this study was to evaluate retrospectively the toxicity and response, bladder preservation, and survival of patients with muscle-invasive bladder cancer treated with multimodality therapy consisting of low-dose radiation therapy (RT) and concurrent intraarterial chemotherapy (IACT). METHODS AND MATERIALS:. Between November 1999 and July 2005, a total of 27 consecutive, previously untreated patients with muscle-invasive bladder cancer underwent transurethral bladder tumor resection followed by concurrent low-dose RT and IACT. Patients who achieved a complete response (CR) were followed up closely without further therapy, and patients who did not achieve a CR underwent further treatment. RESULTS: Complete response was achieved in 22 of 27 patients (81%). Of these 22 patients, 7 developed recurrences, and 3 died of their disease. In five patients who did not achieve CR, one died from bone metastases. The 3-year overall survival rate was 81%, with a median follow-up time of 27 months; and 22 of 27 patients (81%) with a preserved bladder were tumor-free at the last follow-up. Three patients (11%) developed grade 3 acute hematological toxicity. CONCLUSION: Multimodality therapy consisting of low-dose RT and concurrent IACT for muscle-invasive bladder cancer can achieve survival rates similar to those in patients treated with radical cystectomy, with successful bladder preservation and minimal adverse effects.


Prognostic significance of HIF-2alpha expression on tumor infiltrating macrophages in patients with uterine cervical cancer undergoing radiotherapy.

Hypoxia-inducible factor (HIF)-2alpha, a basic helix-loop-helix (bHLH)-PAS protein, is the principal regulator of the hypoxic transcriptional response. An immunohistochemical study reported strong HIF-2alpha expression in the cytoplasm of tumor infiltrative macrophages (TIMs). Thus we assessed the expression of HIF-2alpha in human cervical cancer tissue before radiation therapy and its relationship to the clinical outcome. Seventy three patients with histologically proven primary advanced squamous cell carcinoma of the uterine cervix underwent radiotherapy in Tokushima University Hospital after biopsy specimens were taken. Among 73 specimens stained for HIF-2alpha, 53 (72.6%) exhibited HIF-2alpha immunoreactivity in the TIMs. In only 5 of 73 cases, HIF-2alpha immunoreactivity was observed in the nuclei of tumor cells. The HIF-2alpha positive cell count ratio in TIMs was associated with disease-free survival (DFS) with the worst DFS (p=0.024) being in cases in the group with a high positive cell count ratio. A high HIF-2alpha positive cell count ratio in TIMs increased the risk of local recurrence (p=0.0142). These findings might suggest that the ratio of the HIF-2alpha positive cell in TIMs may be a new predictive indicator for prognosis before radiation therapy for uterine cervical cancer.

The Journal of Medical Investigation : JMI


Can Kampo Therapy prolong the life of cancer patients?

Our policy regarding the performance of radiotherapy to squamous cell carcinoma of the uterine cervix has not changed since 1969. We have already reported the treatment results which were as good as those from other institutions. Since 1978, Kampo therapy was first introduced in the treatment of cancer patients in dealing with problems such as the side effects of radiotherapy and chemotherapy and various types of general malaise. We analyzed our treatment results in order to re-evaluate the chemo-radiotherapy in combination with Kampo. Survival rates for 5, 10 and 15 years, respectively, were 90.9%, 71.6% and 71.6% for Stage IB, 78.9%, 61.8% and 41.8% for Stage II, 62.3%, 49.1% and 41.2% for Stage III and 53.1%, 36.5% and 16.7% for Stage IV. The Kampo significantly extended the survival of patients with uterine cervical cancer. We intend to perform further research with more patients to explore how this therapy contributes to the prolonging of patients survival.


Radiation therapy for cervical cancer in the elderly

To evaluate the long-term results of radical radiation therapy (RT) for cervical cancer in elderly patients. We reviewed the clinical records of 727 patients with cervical cancer who underwent radical RT at the Tokushima University Hospital and compared the treatment results of three age groups: </=64 years (younger group [YG], 337 patients), 65-74 years (young-old group [YOG], 258 patients), and >/=75 years (older group [OG], 132 patients). At the last follow-up, 155 YG (46%), 77 YOG (30%), and 48 OG patients (36%) had died of cervical cancer; the median follow-up periods were 82, 87, and 68 months, respectively. The 5-/10-year disease-specific survival rates were 60%/52% in YG, 76%/68% in YOG, and 66%/57% in OG. Differences between OG and the other groups were not significant. The 5-/10-year disease-specific survival rate of YOG was significantly superior to that of YG (p<0.001). Clinical stage was the only significant prognostic variable (p<0.001). Late radiation morbidity of grades 2-4 in the bladder and/or rectum occurred in 22% of YG, 31% of YOG, and 8% of OG patients. RT was well tolerated in elderly patients, and age was not a significant prognostic factor. In the management of cervical cancer, advanced age is not a contraindication to radical RT.


Randomized Fhase II Study of Immunomodulator Z-100 in Patients with Stage IIIB Cervical Cancer with Radiation Therapy

To find the optimal dose of immunomodulator Z-100 in patients with stage IIIB squamous cell carcinoma of the cervix in combination with radiation therapy. The patients were randomly assigned to the dosage levels of 2, 20 or 40 mug of Z-100. Z-100 was subcutaneously injected twice a week during radiotherapy and once in two weeks during the maintenance period. The response rate after radiotherapy was evaluated, and the optimal clinical dosage was then determined. Safety of Z-100 was evaluated during the radiation therapy and maintenance therapy. Survival was also evaluated. A total of 116 patients were entered. The adverse reactions were not dose-dependent and no serious toxicities were observed. The response rates were 72.2% (26/36) in the 2 microg group, 84.6% (33/39) in the 20 microg group and 94.3% (33/35) in the 40 microg group (P = 0.006). However, the survival was not significantly different. The optimal dose of Z-100 was determined to be 40 mug in combination with radiation therapy for stage IIIB cervical cancer. However, impact of Z-100 on survival must be determined by the placebo controlled randomized trial, because survival benefit was not observed in this small population study.


Quality Assurance of I-125 Seed for Prostate Brachytherapy Using an Imaging Plate

OncoSeed is delivered in a sterile environment in the form of a cartridge, so it is impractical to resterilize and reload seeds after calibration. We investigated a new method using an imaging plate dosimetry system to characterize all seeds in the OncoSeed cartridge in a sterile environment. Seeds within the cartridge were placed on an imaging plate, and the imaging plate irradiated. To remove scatter radiation, and improve spatial resolution of seed images, we used X-ray parallel cross grids. The irradiated imaging plate was scanned using a Bio-imaging Analyzer System, and radioactivity intensities of seed images were given in counts. Counts could be translated to profiles, and each seed within the cartridge was analyzed. Results showed a good correlation between counts and total radioactivity of the seeds within the cartridge. Thus, using a least-squares line, it was possible to characterize a cartridge with unknown apparent activity. By analyzing the profiles, it was possible not only to detect a miscalibrated seed in the cartridge from its relative difference in counts, but also to identify its position in the cartridge. No significant changes in counts were seen between sterile and nonsterile environments. Using an imaging plate dosimetry system, all seeds in a cartridge could be characterized in a sterile environment.

International Journal of Radiation Oncology*Biology*Physics


Phase III double-blind randomized trial of radiation therapy for stage IIIb cervical cancer in combination with low- or high-dose Z-100: Treatment with immunomodulator, more is not better

To evaluate the efficacy of low or high-dose immunomodulator, Z-100, in combination with radiotherapy for cervical cancer. Between 1995 and 1999, 221 patients with stage IIIb squamous cell carcinoma of the cervix were randomly assigned to treatment with Z-100 either at 0.2 microg or 40 microg in a double-blind manner in combination with radiotherapy. The 5-year survival of patients with high-dose and low-dose Z-100 was 41.5% (95% CI: 31.7-51.3%) and 58.2% (95% CI: 48.7-67.7%), respectively, showing a 30% reduction in the death rate (hazard ratio: 0.670 [95% CI: 0.458-0.980], P = 0.039). Survival of high-dose group was equivalent to the 4-year survival of the radiotherapy plus hydroxyurea arm (49.7%) of GOG120 study, and that of low-dose group was similar to the survival of the cisplatin-based chemoradiation arm. The progression-free survival was also significantly improved in favor of low-dose group (hazard ratio: 0.667 [95% CI: 0.447-0.997], P = 0.048). The survival of low-dose group was similar to the survival of the cisplatin-based chemoradiation arms of the GOG120 study. Unexpectedly, the survival of patients with advanced cervical cancer treated by lower dose of Z-100 in combination with radiotherapy was significantly better than those treated with higher dose Z-100, which was equivalent to the survival with radiotherapy alone. The hypothesis that lower dose of Z-100 enhances the efficacy of radiation therapy is now being tested by placebo-controlled randomized trial.


Chemoradiation Therapy for Cervical Cancer:Toxicity of Concurrent Weekly Cisplatio

To retrospectively evaluate the toxicity of concurrent weekly cisplatin and radiation therapy (RT) for locally advanced cervical cancer. Between April 2001 and December 2004, 21 consecutive previously untreated patients with locally advanced cervical cancer were treated with concurrent chemoradiation therapy (CCRT) at the Tokushima University Hospital. Clinical stages were II: 5, III: 15, IVA: 1. External beam radiation therapy (EBRT) was delivered with 10 MV X-rays, 2 Gy fraction per day; total dose to the whole pelvis was 50 Gy. Iridium-192 high-dose-rate (HDR) intracavitary radiation therapy was performed with 10-30 Gy (median, 24 Gy) targeted at point A. Concurrent chemotherapy consisted of cisplatin, administered weekly at a dose of 40 mg/m2 for patients who were younger than 65 years and 30 mg/m2 for those 65 years or over. A maximum single dose of cisplatin, up to 70 mg/body, was administered in 5 cycles during EBRT. A total of 86 cycles of cisplatin were administered to the 21 patients, with a median of 4 cycles (range, 2-5). Severe hematological toxicity occurred in 18 patients (86%), including grade 3 in 17 patients (81%) and grade 4 in one patient (4.8%). Moderate or severe gastrointestinal toxicity occurred in 11 patients (52%), including grade 2 in 10 patients (48%) and grade 3 in one patient (4.8%). The grades of hematological toxicity were significantly greater in the 40 mg/m2 group than in the 30 mg/m2 group. All of the patients who were administered 40 mg/m2 of cisplatin developed grade 3 or greater hematological toxicity, including one patient with grade 4 toxicity. In the 30 mg/m2 group, 3 of 10 patients developed less than grade 3 toxicity, and all patients completed radiation therapy without interruption. The incidence of severe acute hematological toxicity was significantly higher in this study than in previously reported randomized controlled trials (RCTs), especially in the group of 40 mg/m2 cisplatin. A dose of 30 mg/m2 of cisplatin was considered to be feasible in weekly cisplatin and radiation therapy.


Quality Assurance of I-125 Seed Permanent Implant Therapy Using a Self-color Developing Reflection-type Dosimetry Sheet Film

We evaluated a self-color developing sheet-type film for the detection of dead seeds in I-125 permanent implant therapy for prostate cancer. As a preliminary study, we irradiated X-rays to a self-developing reflection-type sheet film and created a relational curve between absorbed dose and film density. I-125 seeds were placed on a film and the approximate absorbed dose of I-125 was calculated from the relational curve of X-rays. A cartridge in which a dead seed was loaded among 10 I-125 seeds was placed on the film and the detectability of the dead seed was evaluated. Using the relational curve of X-rays, it was possible to measure the approximate absorbed dose of I-125 seeds and to easily detect a dead seed at a glance. Using sterilized film, it was possible to detect a dead seed. The self-developing film method is feasible for the detection of a dead seed in a cartridge without re-sterilization of seeds.


Insufficiency fractures following radiation therapy for gynecologic malignancies

The Official Jpurnal of The Japanese Society for Therapeutic Radiology and Oncology


Combined Kampo with Radiation Therapy prolongs survival in patiens with cervical cancer


A comparison of the results of radiotherapy and surgical treatment of tangue cancer


Radiotherapy for cervical cancer - Multi-institute retrospective analysis -

子宮頸癌の放射線治療ー多施設間での比較ー


Radiotherapy for Carcinoma of the Uterine Cervix using Low-Dose-Rate Intercavitary Brachytherapy- A Retrospective Analysis of Pretreatment and Treatment Prognostic Factore-


Clinical optimization study of radiotherapy for esophageal cancer

「食道癌・放射線照射の最適化」に関する臨床研究(最終報告)


Radiation Complications Following Breast Conserving Therapy


Therapy for oral squamous cell carcinoma by tegafur and streptococcal agent OK-432 in combination with radiotherapy : Association of the therapeutic effect with differentiation and apoptosis in the cancer cells

Twenty patients with oral squamous cell carcinoma having mainly stage II or III lesions without distant metastasis, were treated with tegafur and streptococcal agent, OK-432, in combination with radiotherapy. As a consequence, 16 cases among the treated 20 cases showed complete remission by this therapy alone. Especially, we have found that the squamous cell carcinoma arising in non-keratinizing oral epithelium rather than in keratinizing oral epithelium has better response to this therapy. Among the 16 cases with complete remission (CR) by the current therapy, 10 cases were histopathologically diagnosed as well-differentiated squamous cell carcinoma and six cases as moderately differentiated squamous cell carcinoma. When we examined immunohistochemically the expression of various antigens such as proliferating cell nuclear antigen (PCNA), p53 and LeY or the presence of DNA fragmentation by nick-end labelling in the biopsy materials taken at the first visit to our clinic from 20 patients treated with the current therapy, the CR group showed a significantly increased LeY expres-sion level ( p< 0.05) and DNA fragmentation rate (p< 0.05) as compared with the partial response (PR, n= 3) + no change (NC, n= 1) group. On the other hand, the CR group with respect to PCNA expression level was significantly decreased as compared with the PR + NC group ( p< 0.05). From these findings, it can be considered that the therapy for oral squamous cell carcinoma by UFT and OK-432 in combination with radiotherapy is very effective, which may be associated with differentiation or apoptosis in oral squamous carcinoma cells. In addition, we present the clinical findings and results of immunohistochemical staining for the biopsy materials obtained from four CR cases treated with the current therapeutic method.


ヒト気道トリプターゼによるフィブリノーンの分解

ヒト気道トリプターゼによるフィブリノーンの分解

The Japanese Journal of Thoracic Diseases


ヒト喀痰から分離した気道トリプターゼと肥満細胞トリプターゼの性質の比較

ヒト喀痰から分離した気道トリプターゼと肥満細胞トリプターゼの性質の比較


Comparison between high dose-rate and low dose-rate brachytherapy for cervical cancer: Japanese experience with treatment and complication (1975-1985)


放射線療法による白血球減少症に対するロムルチドの臨床的有用性の検討

放射線療法による白血球減少症に対するロムルチドの臨床的有用性の検討

Journal of Clinical and Experimental Medicine


Ninjin-Yoei-Tou in the treatment of Leukopenia and Symptoms Associated with Radiotherapy of Malignant Tumors

悪性腫瘍患者の放射線照射に伴う白血球減少及び自覚症状に対する人参養栄湯の有効性の検討ー非投与群との電話法による多施設比較試験ー


Effect of KRN8601(rhG-CSF) on Leukopenia caused by Radiation Therapy for various malignancy --- A phase III double blind controlled study

悪性腫瘍患者の放射線治療時における白血球減少症に対する KRN8601 (rhG-CSF) の効果について --- 臨床第III相二重盲検比較試験成績

The Journal of Japan Society for Cancer Therapy


Clinical trial of UFT against carcinoma of the Uterine Cervix

子宮頸癌におけるUFTの臨床治験


Clinical results of Radiotherapy for M0 Esophageal Cancer in Japan

食道癌M0症例の放射線治療成績の全国集計

The Journaj of Japan Society for Cancer Therapy


Clinical evaluation of postoperative Radiotherapy for Uterine Cervical Cancer

The Official Jpurnal of The Japanese Society for Therapeutic Radiology and Oncology


放射線治療時の白血球減少症に対するセファランチン(タマサキツヅラフジ抽出アルカロイド)の経口投与の臨床的有用性 --- プラセボを対照とした二重盲検法による90mg,30mg,6mg の比較


放射線治療時の白血球減少症に対するセファランチン(タマサキツヅラフジ抽出アルカロイド)の静脈内点滴投与の臨床的有効性 --- プラセボを対照とした二重盲検法による100mg,50mg,10mg の比較


Clinical efficacy of Z-100 for the treatment of leukopenia caused by Radiotherapy --- A multi-center double-blind comparative study with L-Cystene

放射線治療時の白血球減少に対するZ-100 の臨床効果 --- 多施設二重盲検法によるL-シスチインとの比較


Clinical efficacy of Z-100 for the treatment of leukopenia caused by Radiotherapy --- A multi-center double-blind comparative study with Inosine

放射線治療時の白血球減少に対する Z-100 の臨床効果 --- 多施設二重盲検法によるイノシンとの比較


A study of skeletal metastasis of Carcinoma of the Uterine Cervix

子宮頸癌の骨転移例の検討


An Early Clinical Study of Z-100 in Leukopenia Caused by Radiotherapy

放射線治療による白血球減少症に対するZ-100 臨床成績


Eight Cases of Intracranial Arteriovenous Malformations Conducted Conventional Radiation Therapy

放射線療法を行った頭蓋内動静脈奇形について


Induction of Bone Formation in an Adenoid Cystic Carcinoma of the Maxillary Sinus by Adoptive Immunotherapy Involving Intra-arterial Injection of Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 in Combination with Radiotherapy

A patient with an adenoid cystic carcinoma of the maxillary sinus was treated by adoptive immunotherapy involving intra-arterial injection of lymphokine-activated killer cells (a total number of 7 x 10(7) cells) and recombinant interleukin-2 (a total dose of 2.75 x 10(7) units) in combination with radiotherapy (60Co; total irradiation dose of 5,000 rads). Consequently, it was found that bone formation was induced in the treated tumor, which was then replaced completely by lamellar bone tissue with myxomatous stroma. This finding indicates that the tumor cells composing certain adenoid cystic carcinoma can be converted into normal-appearing, bone-forming cells by current therapy and this differentiation phenomenon leads to cure of the tumor.

Journal of Biological Response Modifiers


Phase II Randomized Clinical Trial of LC9018 Concurrently Used with Radiation in the Treatment of Carcinoma of the Uterine Cervix


Multidisciplinary treatment of carcinoma of the alveolus and gingiva


Combination of Radiotherapy with Chemotherapy using Cisplatin of advanced Esophageal Carcinoma

進行食道癌に対する放射線とシスプラチンを中心とする化学併用治療

The Journal of Japan Society for Cancer Therapy


Restorative effect of MDP-Lys(L18) on leukopenia of cancer patient treated with radiotherapy


Radiation therapy for paraaortic lymph node of Carcinoma of the Uterine Cervix --- II. Complication

子宮頸癌の傍大動脈リンパ節放射線治療 --- II. 障害について


The relation of ras oncogene product p21 expression to clinocopathological status criteria and clinical outcome in squamous cell head and neck cancer


Analysis of 5 year survival of esophageal cancer treated by radiotherapy

食道癌の放射線治療ー5年生存症例の検討ー

International Journal of Clinical Oncology


Radiation therapy for paraaortic lymph node of Carcinoma of the Uterine Cervix --- I. Survival and Prognostic Factor

子宮頸癌の傍大動脈リンパ節放射線治療 --- I. 治療成績と予後因子について


Monoclonal antibody analysis of peripheral blood lymphocyte subpopulations in squamous cell head and neck cancer


Interferon Activity and Its Characterization in the Sera of Patients with Head and Neck Cancer


Effects of intradermal administration of streptococcal preparation OK-432 on interferon and natural killer cell activities in patients with oral cancer


Study of Radiation Proctitis of Cervical Cancer Patients After Treated with External and Intracavitary Irradiatipn

教室における放射線直腸炎の検討


Multi-disciplinary Treatment of Advanced Cancer of the Head and Neck


Postoperative radiotherapy for carcinoma of the uterine cervix


Radiotherapy for carcinoma of the uterine cervix

子宮頸癌の放射線治療成績


Changes in pulmonary arterial blood flow following Cobalt 60 treatment of mammary carcinoma

乳癌術後照射例の局所肺動脈血流障害とデキストラン硫酸エステルの投与効果


Studies of preoperative and postoperative irradiation in patients with carcinoma of the lung

肺癌の術前照射及び術後照射の検討(博士論文)


Results of radiotherapy for the tumor of Nasopharynx

上咽頭腫瘍の放射線治療成績


Pulmonary arterial blood flow and prognosis in patients with primary lung cancer

原発性肺癌の肺動脈血流障害と予後


Biological protection mechanisme in mammalian cells, XVII. Effect of DNA and its precursors on induction of chromosomal aberration by irradiation

The Tokushima Journal of Experimental Medicine


Restorative effects of an alkaline hydrolysis product of yeast RNA(nucleton), adenine and d-AMP on the DNA content of liver cells in irradiation mice


Effects of irradiation on the vascularity of rat lung

肺血管系に対する放射線の影響


Restoration of chromosome aberrations of irradiated tumor cells by DNA and its precursors


Results of post-operative radiotherapy of breast cancer

乳癌の術後放射線治療成績


The present situation about the regional center for standard dose in medicine - Report from the regional center for standard dose in medicine-

医療用線量標準四国地区センターの現状ー「医療用線量標準四国地区センター」からの報告ー

Bulletin of School of Medical Sciences, the University of Tokushima

徳島大学医療技術短期大学部紀要


The Effect of Kampo Formulation on Low bak pain in older Patients

高齢者医療と漢方ー腰痛ー

徳島大学医療技術短期大学部紀要


Is it possible or not calibrate dosimeter by using high-energy photon beams? - A trial report from the Shikoku regional center for standard dose medicine-

校正用線源は高エネルギーX線で可能か

徳島大学医療技術短期大学部紀要


生体防御と補剤ー補剤治療の意義とその位置づけをめぐってー --- 癌の放射線治療における漢方薬の検討


Clinical results of radiotherapy and B-M therapy for advanced cervical cancer

進行子宮頸癌に対する放射線+化学療法(B-M療法)併用における成績

徳島大学医療技術短期大学部紀要


Radiation therapy and Chinese immunotherapy of malignant tumor - from clinical aspects -

放射線と中医免疫ー臨床面からー

徳島大学医療技術短期大学部紀要


A research of subjective complaints in expectoration of sputum in patients with chronic airway diseases through a questionnaire

自覚症状からみた慢性気道疾患患者の痰の喀出状態

徳島大学医療技術短期大学部紀要


Comparison of biochemical characteristics of human airway tryptase and that of lung mast cell tryptase

ヒト喀痰から分離した気道トリプターゼと肥満細胞トリプターゼの性質の比較

徳島大学医療技術短期大学部紀要


Clinical studies of radiotherapy in patients with small call lung cancer

小細胞肺癌の放射線治療による臨床的検討

徳島大学医療技術短期大学部紀要


Activities of serine proteases in lung tissues of rats with bleomycin-induced interstitial pneumonia-pulmonary fibrosis

ブレオマイシン間質性肺炎ー肺線維症ラット肺組織のセリンプロテアーゼ活性ー

徳島大学医療技術短期大学部紀要


Resulta of radium implants for carcinoma of the tongue

小線源による舌癌の放射線治療成績

徳島大学医療技術短期大学部紀要


Low-dose-rate intracavitary brachytherapy for cancer of the uterine cervix

Bulletin of School of Medical Sciences, the University of Tokushima


The present situation about radiation treatments and radiotherapy in the Shikoku area - Report from the regional center for standard dose in medicine -

四国地区における放射線治療装置と放射線治療の現状ー医療用線量標準四国地区センターからの報告ー

徳島大学医療技術短期大学部紀要


Clinical effects of PSK for cancer patients treated with radiotherapy

放射線治療患者の及ぼすPSKの臨床効果

徳島大学医療技術短期大学部紀要


Radiotherapy and Kampotherapy of the cancer

癌の放射線治療と漢方療法

徳島大学医療技術短期大学部紀要


A case of recurrent Squamous Cell Carcinoma of Cervix successfully treated with BOMP

癌性心膜炎，癌性腹膜炎に対する全身BOMP療法が奏効した再発子宮頸癌の1例

Japanese Journal of Cancer and Chemotherapy


An Anal Cancer that responded to Chemoradiotherapy A case report

化学放射線併用療法にて組織学的にCRとなった肛門癌の1症例


Eosinophilic Granuloma in Hypothalamus and Pituitary Gland ; A case report of effective Radiation Therapy

視床下部ー下垂体原発好酸球肉芽腫の放射線治療著効例


The primary therapy of oral squamous cell carcinoma by UFT and OK-432 in combination with Radiotherapy

口腔扁平上皮癌に対するUFT,OK-432, 放射線治療を併用した一次治療